KEGG   DRUG: Inotuzumab ozogamicin
Entry
D08933                      Drug                                   
Name
Inotuzumab ozogamicin (USAN/INN);
Inotuzumab ozogamicin (genetical recombination) (JAN);
Besponsa (TN)
Product
Formula
C6518H10002N1738O2036S42
Exact mass
146542.0817
Mol weight
146632.38
Remark
Therapeutic category: 4239
ATC code: L01FB01
Product: D08933<JP/US>
Efficacy
Antineoplastic, DNA synthesis inhibitor, Anti-CD22 antibody
  Disease
B-cell precursor acute lymphoblastic leukemia [DS:H00001]
  Type
Antibody-drug conjugate
Target
CD22 (SIGLEC2) [HSA:933] [KO:K06467]
  Pathway
hsa04514  Cell adhesion molecules
hsa04640  Hematopoietic cell lineage
hsa04662  B cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FB CD22 (Clusters of Differentiation 22) inhibitors
     L01FB01 Inotuzumab ozogamicin
      D08933  Inotuzumab ozogamicin (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-CD22 Antibodies
    Inotuzumab Ozogamicin
     D08933  Inotuzumab ozogamicin (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   423  Antibiotics
    4239  Others
     D08933  Inotuzumab ozogamicin (USAN/INN); Inotuzumab ozogamicin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   SIGLEC family
    CD22 (SIGLEC2)
     D08933  Inotuzumab ozogamicin (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D08933
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08933
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D08933
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D08933
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D08933
Other DBs
CAS: 635715-01-4
PubChem: 96025616
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system